Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic variants associated mRNA stability in lung.

BMC genomics·2022

Same author

Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer.

PLoS computational biology·2022

Same author

Comparison of the diagnostic efficacy of <sup>68</sup> Ga-FAPI-04 PET/MR and <sup>18</sup>F-FDG PET/CT in patients with pancreatic cancer.

European journal of nuclear medicine and molecular imaging·2022

Same author

Addressing Extreme Propensity Scores in Estimating Counterfactual Survival Functions via the Overlap Weights.

American journal of epidemiology·2022

Same author

68 Ga-FAPI-04 Versus 18 F-FDG PET/CT in a Case of Peutz-Jeghers Syndrome.

Clinical nuclear medicine·2022

Same author

Fatty acid synthase (Fasn) inhibits the expression levels of immune response genes via alteration of alternative splicing in islet cells.

Journal of diabetes and its complications·2022

Same journal

Plant-Derived Polyphenols in the Fight against Colorectal Cancer.

Anti-cancer agents in medicinal chemistry·2026

Same journal

Emerging Frontiers in Nanomedicine for Colorectal Cancer: A Review of Therapeutic Advances, Clinical Evidence, and Patented Technologies.

Anti-cancer agents in medicinal chemistry·2026

Same journal

Microfluidic Synthesis of miR-10a Antisense Oligonucleotides-Loaded LNP Combined with Cisplatin for Colorectal Cancer Therapy.

Anti-cancer agents in medicinal chemistry·2026

Same journal

Synergistic Anticancer Effect of Luteolin and Etoposide via the PI3K/AKT Signaling Pathway.

Anti-cancer agents in medicinal chemistry·2026

Same journal

Targeting Eg5 with K858: A Strategy for Radiosensitization Through ROS-Mediated DNA Damage in Esophageal Squamous Cell Carcinoma.

Anti-cancer agents in medicinal chemistry·2026

Same journal

Pulsatilla chinensis Saponins as Multitargeted Anticancer Agents: A Mini-Review of Molecular Mechanisms and Therapeutic Potential.

Anti-cancer agents in medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 19, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

Cell dormancy and tumor refractory.

Kaixiu Wang¹, Wei Jiang², Chao Cheng³

¹Department of gynaecology, Second People's Hospital of Jingmen, Jingmen, HuBei 448000. China.

Anti-Cancer Agents in Medicinal Chemistry

|September 1, 2012

Summary

This summary is machine-generated.

Tumor dormancy involves quiescent cancer stem-like cells (CSCs) that resist therapy, leading to cancer relapse. Understanding dormancy exit mechanisms is key to developing targeted drugs for eliminating these cells and preventing metastasis.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

Related Experiment Videos

Last Updated: May 19, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

Area of Science:

Oncology
Cancer Biology
Cellular and Molecular Medicine

Background:

Metastasis and tumor relapse are primary causes of cancer mortality, often occurring years after initial treatment.
Residual tumor cells in a dormant state contribute to late-stage cancer recurrence and treatment resistance.

Purpose of the Study:

To review the mechanisms of tumor dormancy, its association with cancer stem-like cells (CSCs), and the role of the angiogenic switch.
To highlight the need for better experimental models and biomarkers for dormant tumor cells.

Main Methods:

Literature review focusing on tumor dormancy, CSCs, and angiogenesis.
Analysis of molecular profiles associated with dormant states.

Main Results:

Tumor dormancy is characterized by quiescent CSCs exhibiting balanced cell death/proliferation, immune evasion, and resistance to conventional therapies.
Dormancy involves cell cycle arrest, non-angiogenic properties, and limited metastatic potential.

Conclusions:

Clarifying the regulatory mechanisms governing entry and exit from tumor dormancy is crucial for developing strategies to eliminate residual disease.
Targeted therapies aimed at eradicating dormant CSCs are essential for preventing distant relapse and improving long-term cancer patient outcomes.